A GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's disease.
Parkinson's disease (PD) is a chronic disorder with no disease-modifying treatment available. The glucagon-like peptide-1 (GLP-1) class of drugs is on the market to treat diabetes and obesity. GLP-1 drugs have also shown neuroprotective effects in animal models and clinical trials in PD patients. Apelin (APJ) is an adi...